KAREN BULAONG: Open Payments
NPI 1063110385 · CHERRY HILL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,384 in 135 payments from 22 companies in 2025. Trend: 2023 $499 · 2024 $1,256 · 2025 $2,384
Food & beverage: $2,384
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 65 | $673 |
| UCB, Inc. | 16 | $440 |
| Axsome Therapeutics, Inc. | 4 | $187 |
| Neurelis, Inc. | 3 | $161 |
| Lilly USA, LLC | 2 | $130 |
| Neurocrine BioSciences, Inc. | 6 | $116 |
| Biogen, Inc. | 4 | $87 |
| PFIZER INC. | 4 | $76 |
| Impel Pharmaceuticals LLC | 4 | $76 |
| Aucta Pharmaceuticals, Inc. | 6 | $69 |
Products named: UBRELVY, QULIPTA, Nayzilam, Symbravo, Briviact, VALTOCO, KISUNLA, INGREZZA.
Industry payments across NJ — which companies pay providers there.
